A large retrospective cohort study based on data from the U.S. Department of Veterans Affairs addressed the question of whether treatment with the antiviral drug nirmatrelvir within five days of positive SARS-CoV-2 testing reduces the risk of post-acute sequelae of covid disease. Nirmatrelvir was shown to reduce the risk of both long-covid and hospitalization and post-acute death at 180 days.
This content is machine-translated. Please contact us if you need professional translation services.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Cardiovascular risk in IBD
Cause for concern?
- Microplastics in kidneys and urine
Life in plastic … is not fantastic
- Asthma and psyche
When fear makes you lose your breath
- COPD: Update for the primary care physician
Counteract exacerbations and improve quality of life
- Stroke
Not on the brain – the latest findings on strokes
- Atopic dermatitis: choice of systemic therapy option
“It’s always an individual weighing”.
- Do low carb diets harm the heart?
Keto diet associated with hypercholesterolemia and increased risk of ASCVD
- Cardiovascular events in CKD